• What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    • Moss KM, Mishra GD, Krejany EO, Hickey M.
    • Gynecol Oncol. 2022 Oct;167(1):58-64. doi: 10.1016/j.ygyno.2022.07.029. Epub 2022 Aug 4.
    • Surgical Menopause and Bilateral Oophorectomy: Effect of Estrogen-Progesterone and Testosterone Replacement Therapy on Psychological Well-being and Sexual Functioning; A Systematic Literature Review.
    • Stuursma A, Lanjouw L, Idema DL, de Bock GH, Mourits MJE.
    • J Sex Med. 2022 Sep 26:S1743-6095(22)01769-6. doi: 10.1016/j.jsxm.2022.08.191. Epub ahead of print.

    Related:

    Review registration number: CRD42019136698: The effect of hormone replacement therapy on psychological well-being and sexual functioning in women after treatment-induced menopause. (PROSPERO register)

    • Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.
    • Bernstein-Molho R, Friedman E, Evron E.
    • Cancers (Basel). 2022 Sep 22;14(19):4592. doi: 10.3390/cancers14194592.
    • Scene memory and hippocampal volume in middle-aged women with early hormone loss.
    • Gervais NJ, Gravelsins L, Brown A, Reuben R, Karkaby L, Baker-Sullivan E, Mendoza L, Lauzon C, Almey A, Foulkes WD, Bernardini MQ, Jacobson M, Velsher L, Rajah MN, Olsen RK, Grady C, Einstein G.
    • Neurobiol Aging. 2022 Sep;117:97-106. doi: 10.1016/j.neurobiolaging.2022.05.003. Epub 2022 May 13.
    • Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants.
    • Edaily S, Abdel-Razeq H.
    • Onco Targets Ther. 2022 Jul 27;15:815-826. doi: 10.2147/OTT.S369844.
    • Study: Risk-reducing ovarian cancer surgery and quality of life.
    • [No author given]
    • FORCE. XRAY. 2022 Jul 26.

    Related:

    Original research:

    Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.

    • Trajectories of metabolic parameters after bilateral oophorectomy in premenopausal women.
    • Kapoor E, Faubion SS, Gazzuola Rocca L, Mielke MM, Smith CY, Rocca WA.
    • Maturitas. 2022 Jul 21;165:38-46. doi: 10.1016/j.maturitas.2022.07.005. Epub ahead of print.
    • Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey.
    • Massarotti C, Buonomo B, Dellino M, Campanella M, De Stefano C, Ferrari A, Anserini P, Lambertini M, Peccatori FA.
    • Cancers (Basel). 2022 Jul 15;14(14):3457. doi: 10.3390/cancers14143457.
    • Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.
    • Mai PL, Miller A, Black A, Falk RT, Boggess JF, Tucker K, Stuckey AR, Rodriguez GC, Wong C, Amatruda TT, Wilkinson KJ, Modesitt SC, Yamada SD, Bixel KL, Glaser GE, Rose PG, Greene MH, Sherman ME.
    • Am J Obstet Gynecol. 2022 Jul;227(1):61.e1-61.e18. doi: 10.1016/j.ajog.2022.02.022. Epub 2022 Feb 22.
    • Changes in Sex Steroids and Relation With Menopausal Complaints in Women Undergoing Risk-reducing Salpingo-oophorectomy.
    • van Winden LJ, Vermeulen RFM, van den Noort V, Gaarenstroom KN, Kenter GG, Brood-van Zanten MMA, Korse CM, van Beurden M, van Rossum HH.
    • J Endocr Soc. 2022 Apr 25 [eCollection 2022 Jun];6(6):bvac069. doi: 10.1210/jendso/bvac069.
    • Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    • Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips KA, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):540-552. doi: 10.1093/jnci/djac004.

    Related:

    Commentary:

    Oral Contraceptives and BRCA Cancer: A Balancing Act.

    • Major clinical research advances in gynecologic cancer in 2021.
    • Park JY, Lee JY, Lee YY, Shim SH, Suh DH, Kim JW.
    • J Gynecol Oncol. 2022 Mar;33(2):e43. doi: 10.3802/jgo.2022.33.e43.
    • Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
    • Manchanda R, Gaba F, Talaulikar V, Pundir J, Gessler S, Davies M, Menon U; Royal College of Obstetricians and Gynaecologists.
    • BJOG. 2022 Jan;129(1):e16-e34. doi: 10.1111/1471-0528.16896. Epub 2021 Oct 20.
    • Menopausal hormone therapy and breast cancer risk.
    • Rozenberg S, Di Pietrantonio V, Vandromme J, Gilles C.
    • Best Pract Res Clin Endocrinol Metab. 2021 Dec;35(6):101577. doi: 10.1016/j.beem.2021.101577. Epub 2021 Sep 10.
    • Review
    • Guideline No. 422f: Menopause and Breast Cancer.
    • Jacobson M, Mills K, Graves G, Wolfman W, Fortier M.
    • J Obstet Gynaecol Can. 2021 Dec;43(12):1450-1456.e1. doi: 10.1016/j.jogc.2021.09.011. Epub 2021 Nov 17.
    • Guideline
    • Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment.
    • Rocca WA, Lohse CM, Smith CY, Fields JA, Machulda MM, Mielke MM.
    • JAMA Netw Open. 2021 Nov 1;4(11):e2131448. doi: 10.1001/jamanetworkopen.2021.31448.

    Related:

    Commentary:

    Long-term Risk of Cognitive Impairment and Dementia Following Bilateral Oophorectomy in Premenopausal Women-Time to Rethink Policies?

    • What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Brand A, Kirk J, Symecko HL, Domchek SM, Tejada-Berges T, Trainer A, Mishra GD.
    • Gynecol Oncol. 2021 Oct;163(1):148-154. doi: 10.1016/j.ygyno.2021.07.029. Epub 2021 Jul 24.
    • BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study.
    • Grandi G, Boggio Sola V, Cortesi L, Toss A, Giuliani GA, Del Savio MC, Facchinetti F.
    • Psychooncology. 2021 Oct;30(10):1711-1719. doi: 10.1002/pon.5714. Epub 2021 May 28.
    • Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline.
    • Jacobson M, Coakley N, Bernardini M, Branco KA, Elit L, Ferguson S, Kim R.
    • Hered Cancer Clin Pract. 2021 Sep 26;19(1):39. doi: 10.1186/s13053-021-00196-9.
    • A rare case of breast cancer in a transgender woman.
    • Sieberg R, Soriano K, Zuurbier R.
    • Radiol Case Rep. 2021 Aug 26;16(11):3285-3288. doi: 10.1016/j.radcr.2021.07.052.
    • The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    • Kershaw V, Hickey I, Wyld L, Jha S.
    • Eur J Obstet Gynecol Reprod Biol. 2021 Aug 8;265:7-17. doi: 10.1016/j.ejogrb.2021.08.001. Epub ahead of print.
    • Review
    • Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    • Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas AHEM, Prins JB, Bulten J, Teerenstra S, van Bommel MHD, van Doorn HC, Mourits MJE, van Beurden M, Zweemer RP, Gaarenstroom KN, Slangen BFM, Brood-van Zanten MMA, Vos MC, Piek JMJ, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, Massuger LFAG, IntHout J, Hermens RPMG, de Hullu JA.
    • JAMA Oncol. 2021 Aug 1;7(8):1203-1212. doi: 10.1001/jamaoncol.2021.1590.

    Related:

    Identifier: NCT02321228: Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (TUBA). (ClinicalTrials.gov)

    Research news: Study: Risk-reducing ovarian cancer surgery and quality of life. (FORCE. XRAY.)

    • What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Domchek SM, Kirk J, Brand A, Trainer A, Mishra GD, Baker FC.
    • Gynecol Oncol. 2021 Aug;162(2):447-453. doi: 10.1016/j.ygyno.2021.05.036. Epub 2021 Jun 8.
    • Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers - an Israeli matched pair study.
    • Perri T, Levin G, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J.
    • Int J Gynaecol Obstet. 2021 Jul 29. doi: 10.1002/ijgo.13843. Epub ahead of print.
    • An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    • Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, Foulkes WD, McKinnon W, Panchal S, Cohen SA, Sun S, Sun P, McKetton L, Troyer AK, Narod SA.
    • Cancer. 2021 Jun 2. doi: 10.1002/cncr.33654. Epub ahead of print.
    • What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    • Hickey M, Moss KM, Mishra GD, Krejany EO, Domchek SM, Wark JD, Trainer A, Wild RA.
    • Gynecol Oncol. 2021 Jul;162(1):88-96. doi: 10.1016/j.ygyno.2021.04.038. Epub 2021 May 7.
    • Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article.
    • Sourouni M, Kiesel L.
    • Geburtshilfe Frauenheilkd. 2021 May;81(5):549-554. doi: 10.1055/a-1390-4353. Epub 2021 May 20.
    • What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    • Hickey M, Moss KM, Brand A, Wrede CD, Domchek SM, Meiser B, Mishra GD, Joffe H.
    • Gynecol Oncol. 2021 May;161(2):527-534. doi: 10.1016/j.ygyno.2021.02.001. Epub 2021 Feb 11.
    • Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
    • Huber D, Seitz S, Kast K, Emons G, Ortmann O.
    • J Cancer Res Clin Oncol. 2021 Apr 22. doi: 10.1007/s00432-021-03629-z. Epub ahead of print.
    • The management of menopausal symptoms in women following treatment for cancer at a specialist menopause service.
    • Chakrabarti R, Holloway D, Bruce D, Rymer J.
    • Post Reprod Health. 2021 Apr 7:20533691211000548. doi: 10.1177/20533691211000548. Epub ahead of print.
    • Why So Many of Us Quit Taking Tamoxifen.
    • Horner K.
    • FORCE. Blog. 2021 Apr 6.

    Related:

    Research news: Study: How breast cancer patients experience hormone therapy (FORCE. XRAY.)

    • Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    • Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S.
    • Eur J Cancer. 2021 Mar 16;148:95-102. doi: 10.1016/j.ejca.2021.02.007. Epub ahead of print.
    • A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    • Islam RM, Davis SR, Bell RJ, Tejada-Berges T, Wrede CD, Domchek SM, Meiser B, Kirk J, Krejany EO, Hickey M.
    • Menopause. 2021 Mar 15;28(7):748-755. doi: 10.1097/GME.0000000000001766.
    • Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer.
    • Brennan A, Brennan D, Rees M, Hickey M.
    • Int J Gynecol Cancer. 2021 Mar;31(3):352-359. doi: 10.1136/ijgc-2020-002032. Epub 2020 Oct 30.
    • Review
    • Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    • Grandi G, Sammarini M, Cortesi L, Toss A, Botticelli L, Varliero F, Sighinolfi G, Barbieri E, Facchinetti F.
    • Menopause. 2021 Feb 1. doi: 10.1097/GME.0000000000001737. Epub ahead of print.
    • Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study).
    • Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, van Beurden M, Roeters van Lennep JE, van Doorn HC, de Hullu JA, Mom C, van Dorst EBL, Mourits MJE, Slangen BFM, Gaarenstroom KN, Zillikens MC, Leiner T, van der Kolk L, Collee M, Wevers M, Ausems MGEM, van Engelen K, Berger LP, van Asperen CJ, Gomez-Garcia EB, van de Beek I, Rookus MA, Hauptmann M, Bleiker EM, Schagen SB, Aaronson NK, Maas AHEM, van Leeuwen FE.
    • JMIR Res Protoc. 2021 Jan 22;10(1):e24414. doi: 10.2196/24414.

    Related:

    Study Record Detail: Health After eaRly Menopause Due to Oophorectomy (HARMOny). (ClinicalTrials.gov)

    • Study: Women support delayed removal of ovaries.
    • [No author given]
    • FORCE. XRAY. 2020 Dec 24.

    Related:

    Original research:

    Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

    • The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies.
    • Hickey I, Jha S, Wyld L.
    • Gynecol Oncol. 2020 Dec 11:S0090-8258(20)34164-0. doi: 10.1016/j.ygyno.2020.12.001. Epub ahead of print.
    • Review
    • Two-Stage Surgery to Reduce Ovarian Cancer Risk Piques Interest.
    • Worcester S.
    • Medscape. News & Perspective. 2020 Oct 16.

    Related:

    Original research:

    Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

    • Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital.
    • Trister R, Jacobson M, Nguyen P, Sobel M, Allen L, Narod SA, Kotsopoulos J.
    • Fam Cancer. 2020 Sep 23. doi: 10.1007/s10689-020-00208-y. Epub ahead of print.
    • Cardiovascular Prevention in Individuals at High Risk of Developing Cancer.
    • Oren O, Kopecky SL, Blumenthal RS, Gersh BJ, Yang EH.
    • JACC CardioOncol. 2020 Sep 15;2(3):527-531. doi: 10.1016/j.jaccao.2020.07.002.
    • Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
    • Gaba F, Blyuss O, Chandrasekaran D, Osman M, Goyal S, Gan C, Izatt L, Tripathi V, Esteban I, McNicol L, Ragupathy K, Crawford R, Evans DG, Legood R, Menon U, Manchanda R.
    • BJOG. 2020 Aug 16. doi: 10.1111/1471-0528.16424. Epub ahead of print.

    Related:

    Commentary:

    Attitudes towards risk-reducing salpingectomy: listen to the patients.

    Press: Two-Stage Surgery to Reduce Ovarian Cancer Risk Piques Interest (Medscape. News & Perspective.)

    Research news: Study: Women support delayed removal of ovaries (FORCE. XRAY.)

    • Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
    • Mejia-Gomez J, Gronwald J, Senter L, Karlan BY, Tung N, Wolfman W, Demsky R, Sun P, Narod SA, Kotsopoulos J; and the Hereditary Breast Cancer Clinical Study Group.
    • Menopause. 2020 Aug 10. doi: 10.1097/GME.0000000000001629. Epub ahead of print.
    • Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.
    • Silva Filho ALD, Carvalho GM, Sena LC, Gomes LPG, Valério MFH, Martins RIL, Cândido EB.
    • Rev Assoc Med Bras (1992). 2020 Aug;66(8):1134-1138. doi: 10.1590/1806-9282.66.8.1134.
    • Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database.
    • Dominguez-Valentin M, Seppälä TT, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W, Vangala D, Perne C, Strauß HG, Tecklenburg J, Holinski-Feder E, Steinke-Lange V, Mecklin JP, Plazzer JP, Pineda M, Navarro M, Vidal JB, Kariv R, Rosner G, Piñero TA, Gonzalez ML, Kalfayan P, Sampson JR, Ryan NAJ, Evans DG, Møller P, Crosbie EJ.
    • J Clin Med. 2020 Jul 18;9(7):2290. doi: 10.3390/jcm9072290.
    • Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?
    • Grandi G, Caroli M, Cortesi L, Toss A, Tazzioli G, Facchinetti F.
    • Expert Opin Drug Saf. 2020 Jul 10:1-6. doi: 10.1080/14740338.2020.1791818. Epub ahead of print.
    • Review
    • Lifestyle Choices May Reduce Breast Cancer Risk Regardless of Genetics.
    • Otto MA.
    • Medscape. 2020 Jul 7.

    Related:

    Original research:

    Association of Nongenetic Factors With Breast Cancer Risk in Genetically Predisposed Groups of Women in the UK Biobank Cohort.

    Research news: Lifestyle choices may reduce breast cancer risk regardless of genetics. (MDedge | Hematology & Oncology)

    • The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study.
    • Grandi G, Del Savio MC, Sammarini M, Cortesi L, Toss A, Piombino C, Facchinetti F.
    • Eur J Cancer Prev. 2020 Jun 8. doi: 10.1097/CEJ.0000000000000606. Epub ahead of print.
    • Factors associated with counseling and postoperative hormone therapy use in surgically menopausal women.
    • Verrilli L, Brown H, Williams M.
    • Menopause. 2020 May 11. doi: 10.1097/GME.0000000000001560. Epub ahead of print.
    • Cognitive markers of dementia risk in middle-aged women with bilateral salpingo-oophorectomy prior to menopause.
    • Gervais NJ, Au A, Almey A, Duchesne A, Gravelsins L, Brown A, Reuben R, Baker-Sullivan E, Schwartz DH, Evans K, Bernardini MQ, Eisen A, Meschino WS, Foulkes WD, Hampson E, Einstein G.
    • Neurobiol Aging. 2020 Apr 29;94:1-6. doi: 10.1016/j.neurobiolaging.2020.04.019. Epub ahead of print.
    • Hormone Therapy Use After Premature Surgical Menopause Based on Prescription Records: A Population-Based Study.
    • Jang JH, Arora N, Kwon JS, Hanley GE.
    • J Obstet Gynaecol Can. 2020 Apr 27:S1701-2163(20)30336-4. doi: 10.1016/j.jogc.2020.03.022. Epub ahead of print.
    • Risk of cardiovascular disease after preventive salpingo-oophorectomy.
    • Johansen N, Tonstad S, Liavaag AH, Selmer RM, Tanbo TG, Michelsen TM.
    • Int J Gynecol Cancer. 2020 Apr 23. pii: ijgc-2019-000856. doi: 10.1136/ijgc-2019-000856. [Epub ahead of print]
    • Association of Nongenetic Factors With Breast Cancer Risk in Genetically Predisposed Groups of Women in the UK Biobank Cohort.
    • Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR.
    • JAMA Netw Open. 2020 Apr 1;3(4):e203760. doi: 10.1001/jamanetworkopen.2020.3760.
    • Hormone Replacement Therapy Prescription After Premature Surgical Menopause.
    • Garg N, Behbehani S, Kosiorek H, Wasson M.
    • J Minim Invasive Gynecol. 2020 Mar 12. pii: S1553-4650(20)30124-2. doi: 10.1016/j.jmig.2020.03.002. [Epub ahead of print]
    • Clinical Effects of Early or Surgical Menopause.
    • Kingsberg SA, Larkin LC, Liu JH.
    • Obstet Gynecol. 2020 Mar 10. doi: 10.1097/AOG.0000000000003729. [Epub ahead of print]
    • Review
    • Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?
    • Mills KA, Joshi TV, West L, Kuznicki M, Kent L, Hokenstad AN, Cripe JC, Woolfolk C, Senter L, Bakkum-Gamez JN, Wenham RM, Cohn DE, Bae-Jump V, Thaker PH.
    • Gynecol Oncol. 2020 Mar 3. pii: S0090-8258(20)30179-7. doi: 10.1016/j.ygyno.2020.02.033. [Epub ahead of print]
    • Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society.
    • Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, Iglesias D, Pothuri B.
    • Gynecol Oncol. 2020 Feb 14. pii: S0090-8258(20)30088-3. doi: 10.1016/j.ygyno.2020.01.035. [Epub ahead of print]
    • Guidelines
    • Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
    • Gaba F, Manchanda R.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Feb 4. pii: S1521-6934(20)30018-3. doi: 10.1016/j.bpobgyn.2020.01.006. [Epub ahead of print]
    • Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
    • Swanson CL, Bakkum-Gamez JN.
    • Clin Obstet Gynecol. 2019 Nov 22. doi: 10.1097/GRF.0000000000000499. [Epub ahead of print]
    • Review
    • Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study.
    • Abildgaard J, Ahlström MG, Nielsen DL, Daugaard G, Lindegaard B, Obel N, Lidegaard Ø.
    • Psychooncology. 2019 Nov 16. doi: 10.1002/pon.5290. [Epub ahead of print]
    • Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    • Perri T, Farhadian Y, Friedman E, Korach J.
    • Menopause. 2019 Nov 4. doi: 10.1097/GME.0000000000001432. [Epub ahead of print]
    • Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
    • Kotsopoulos J, Gronwald J, Lubinski J, McCuaig J, Lynch HT, Neuhausen SL, Foulkes WD, Weitzel JN, Senter L, Tung N, Eng C, Karlan B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Menopause. 2019 Oct 21. doi: 10.1097/GME.0000000000001437. [Epub ahead of print]
    • Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review.
    • Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T.
    • Fertil Steril. 2019 Oct 3. pii: S0015-0282(19)31982-X. doi: 10.1016/j.fertnstert.2019.07.1349. [Epub ahead of print]
    • Review
    • What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
    • Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M.
    • Menopause. 2019 Sep 16. doi: 10.1097/GME.0000000000001421. [Epub ahead of print]
    • Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review.
    • Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T.
    • Gynecol Oncol. 2019 Aug 22. pii: S0090-8258(19)31333-2. doi: 10.1016/j.ygyno.2019.06.017. [Epub ahead of print]
    • Review
    • Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.
    • Walker M, Jacobson M, Sobel M.
    • CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281.
    • Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation.
    • Kotsopoulos J, Hall E, Finch A, Hu H, Murphy J, Rosen B, Narod SA, Cheung AM.
    • JAMA Netw Open. 2019 Aug 2;2(8):e198420. doi: 10.1001/jamanetworkopen.2019.8420.
    • Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    • Gasparri ML, Taghavi K, Fiacco E, Zuber V, Di Micco R, Gazzetta G, Valentini A, Mueller MD, Papadia A, Gentilini OD.
    • Medicina (Kaunas). 2019 Jul 29;55(8). pii: E415. doi: 10.3390/medicina55080415.
    • How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations?
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Related:

    Original research:

    Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

    • Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
    • Moreno AC, Sahni SK, Smith TL, Batur P.
    • Cleve Clin J Med. 2019 Jun;86(6):400-406. doi: 10.3949/ccjm.86a.18130.
    • Hormone-based strategies for management of BrCa1 and 2 carriers.
    • Santen R.
    • Maturitas. 2019 Jun;124:120-121. doi: 10.1016/j.maturitas.2019.04.034.
    • Conference abstract, Review
    • Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2
    • Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.
    • Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.
    • Review

    Related:

    Commentary: How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations? (Medscape Oncology)

    • Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
    • Vermeulen RFM, Korse CM, Kenter GG, Brood-van Zanten MMA, Beurden MV.
    • Climacteric. 2019 Mar 25:1-9. doi: 10.1080/13697137.2019.1582622. [Epub ahead of print]
    • Review
    • The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions.
    • Temkin SM, Mallen A, Bellavance E, Rubinsak L, Wenham RM.
    • Cancer. 2019 Feb 15;125(4):499-514. doi: 10.1002/cncr.31911. Epub 2018 Dec 20.
    • Review
    • Determinants of hormone therapy uptake and decision-making after bilateral oophorectomy (BO): A narrative review.
    • Siyam T, Carbon J, Ross S, Yuksel N.
    • Maturitas. 2019 Feb;120:68-76. doi: 10.1016/j.maturitas.2018.11.005. Epub 2018 Nov 12.
    • Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy.
    • Chan JL, Senapati S, Johnson LNC, DiGiovanni L, Voong C, Butts SF, Domchek SM.
    • Menopause. 2019 Feb;26(2):132-139. doi: 10.1097/GME.0000000000001176.
    • Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.
    • Deli T, Orosz M, Jakab A.
    • Pathol Oncol Res. 2019 Jan 8. doi: 10.1007/s12253-018-00569-x. [Epub ahead of print]
    • Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    • Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J.
    • Gynecol Oncol. 2019 Jan;152(1):145-150. doi: 10.1016/j.ygyno.2018.10.040. Epub 2018 Nov 7.
    • Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers.
    • D'Alonzo M, Piva E, Pecchio S, Liberale V, Modaffari P, Ponzone R, Biglia N.
    • Clin Breast Cancer. 2018 Dec;18(6):e1361-e1366. doi: 10.1016/j.clbc.2018.07.015. Epub 2018 Jul 26.
    • Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
    • Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V, Benedetti Panici P.
    • Crit Rev Oncol Hematol. 2018 Dec;132:111-115. doi: 10.1016/j.critrevonc.2018.09.018. Epub 2018 Oct 3.
    • Review
    • Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations.
    • Powell CB, Alabaster A, Armstrong MA, Stoller N, Raine-Bennett T.
    • Gynecol Oncol. 2018 Dec;151(3):489-493. doi: 10.1016/j.ygyno.2018.10.010. Epub 2018 Oct 10.
    • No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    • Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.
    • J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.
    • Guidelines

    Related:

    [Article in French]:

    No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire.

    • Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 7.

    Related:

    Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

    • Change in Inflammatory Biomarkers and Adipose Tissue in BRCA1/2+ Breast Cancer Survivors Following a Yearlong Lifestyle Modification Program.
    • Sturgeon KM, Foo W, Heroux M, Schmitz K.
    • Cancer Prev Res (Phila). 2018 Sep;11(9):545-550. doi: 10.1158/1940-6207.CAPR-18-0098. Epub 2018 Jun 20.
    • Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
    • Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • JAMA Oncol. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211.

    Related:

    Research News: Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation. (FORCE, XRAYS)

    Commentary, Video: Menopausal Hormone Therapy and Risk for Breast Cancer in BRCA1 Mutation Carriers. (Medscape)

    • The risk of stroke after bilateral salpingo-oophorectomy at hysterectomy for benign diseases: A nationwide cohort study.
    • Lai JC, Chou YJ, Huang N, Chen HH, Wang KL, Wang CW, Shen IH, Chang HC.
    • Maturitas. 2018 Aug;114:27-33. doi: 10.1016/j.maturitas.2018.05.007. Epub 2018 May 19.
    • Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer.
    • Abildgaard J, Ahlström MG, Daugaard G, Nielsen DL, Tønnes Pedersen A, Lindegaard B, Obel N.
    • JNCI Cancer Spectrum. 2018 Jul 1;2(3):pky034. doi: 10.1093/jncics/pky034.
    • A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.
    • Harmsen MG, Steenbeek MP, Hoogerbrugge N, van Doorn HC, Gaarenstroom KN, Vos MC, Massuger LFAG, de Hullu JA, Hermens RPMG.
    • Health Expect. 2018 Jun;21(3):659-667. doi: 10.1111/hex.12661. Epub 2017 Dec 27.
    • Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy.
    • Johansen N, Liavaag AH, Mørkrid L, Michelsen TM.
    • Sex Med. 2018 Jun;6(2):143-153. doi: 10.1016/j.esxm.2018.02.002. Epub 2018 Apr 7.
    • Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
    • Stuursma A, van Driel CMG, Wessels NJ, de Bock GH, Mourits MJE.
    • Maturitas. 2018 May;111:69-76. doi: 10.1016/j.maturitas.2018.01.012. Epub 2018 Jan 13.
    • Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.
    • Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ.
    • Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z.
    • Review
    • Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.
    • Birrer N, Chinchilla C, Del Carmen M, Dizon DS.
    • Am J Clin Oncol. 2018 Mar;41(3):313-315. doi: 10.1097/COC.0000000000000269.
    • Review
    • Commercially Available Lifestyle Modification Program Decreases Inflammatory Biomarkers in BRCA1/2+ Breast Cancer Survivors.
    • Sturgeon KM, Foo W, Schmitz KH/
    • Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):357-357. doi: 10.1158/1055-9965.EPI-18-0063.
    • Conference abstract
    • Bone loss in women with BRCA1 and BRCA2 mutations.
    • Powell CB, Alabaster A, Stoller N, Armstrong MA, Salyer C, Hamilton I, Raine-Bennett T.
    • Gynecol Oncol. 2018 Mar;148(3):535-539. doi: 10.1016/j.ygyno.2018.01.013.
    • Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers.
    • Arts-de Jong M, van Westerop LL, Hoogerbrugge N, Massuger LF, Maas AH, van Beek MH, de Hullu JA.
    • Maturitas. 2018 Feb;108:13-17. doi: 10.1016/j.maturitas.2017.11.002. Epub 2017 Nov 3.
    • Surveillance report 2018 – Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (2013) NICE guideline CG164 [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Murray A.
    • London: National Institute for Health and Care Excellence (UK); 2018 Jan.

    • Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.
    • De Felice F, Marchetti C, Boccia SM, Romito A, Sassu CM, Porpora MG, Muzii L, Tombolini V, Benedetti Panici P.
    • Cancer Treat Rev. 2017 Dec;61:1-5. doi: 10.1016/j.ctrv.2017.09.005. Epub 2017 Sep 28.
    • Review
    • What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk premenopausal women.
    • Hickey M, Trainer A, Braat S, Davey MA, Krejany E, Wark J.
    • BMJ Open. 2017 Nov 14;7(11):e018758. doi: 10.1136/bmjopen-2017-018758.
    • The management of sexuality, intimacy, and menopause symptoms (SIMS) after prophylactic bilateral salpingo-oophorectomy: How to maintain sexual health in "previvors".
    • Alexandre M, Black J, Whicker M, Minkin MJ, Ratner E.
    • Maturitas. 2017 Nov;105:46-51. doi: 10.1016/j.maturitas.2017.06.003. Epub 2017 Jun 3.
    • Review
    • Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
    • Vermeulen RFM, Beurden MV, Kieffer JM, Bleiker EMA, Valdimarsdottir HB, Massuger LFAG, Mourits MJE, Gaarenstroom KN, van Dorst EBL, van der Putten HWHM, Aaronson NK.
    • Eur J Cancer. 2017 Oct;84:159-167. doi: 10.1016/j.ejca.2017.07.018. Epub 2017 Sep 4.
    • [Satisfaction and overall quality of life in BRCA positive women after prophylactic surgeries].
    • Šašková P, Pavlišta D, Dostálek L.
    • Rozhl Chir. 2017 Fall;96(8):328-333.
    • Review, [Article in Czech]
    • Hormonal contraception and breast cancer, what more do we need to know?
    • Marsden J.
    • Post Reprod Health. 2017 Sep;23(3):116-127. doi: 10.1177/2053369117715370. Epub 2017 Jun 22.
    • Review
    • Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.
    • Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM.
    • Acta Obstet Gynecol Scand. 2017 May;96(5):547-555. doi: 10.1111/aogs.13120. Epub 2017 Mar 27.
    • Commercially available lifestyle modification program: randomized controlled trial addressing heart and bone health in BRCA1/2+ breast cancer survivors after risk-reducing salpingo-oophorectomy.
    • Sturgeon KM, Dean LT, Heroux M, Kane J, Bauer T, Palmer E, Long J, Lynch S, Jacobs L, Sarwer DB, Leonard MB, Schmitz K.
    • J Cancer Surviv. 2017 Apr;11(2):246-255. doi: 10.1007/s11764-016-0582-z. Epub 2016 Nov 21.
    • The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review.
    • Siyam T, Ross S, Campbell S, Eurich DT, Yuksel N.
    • BMC Womens Health. 2017 Mar 21;17(1):22. doi: 10.1186/s12905-017-0370-6.
    • Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    • Guidozzi F.
    • Climacteric. 2016 Oct;19(5):419-22. doi: 10.1080/13697137.2016.1209396. Epub 2016 Jul 16.
    • Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report.
    • Signorelli M, Bogani G, Ditto A, Martinelli F, Chiappa V, Lopez C, Scaffa C, Lorusso D, Raspagliesi F.
    • Minerva Ginecol. 2016 Oct;68(5):536-43. Epub 2016 Feb 4.
    • Review
    • Use of systemic hormone therapy in BRCA mutation carriers.
    • Domchek S, Kaunitz AM.
    • Menopause. 2016 Sep;23(9):1026-7. doi: 10.1097/GME.0000000000000724.
    • Review
    • Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    • Karam A.
    • N Engl J Med. 2016 Jun 16;374(24):2403. doi: 10.1056/NEJMc1602861#SA1.

    Related:

    Review

    The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

    Comment / Letter

    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

    Comment / Letter

    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

    • An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
    • Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teulé A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E.
    • Breast Cancer Res Treat. 2016 Jun;157(2):319-27. doi: 10.1007/s10549-016-3805-0. Epub 2016 Apr 27.
    • Committee Opinion No. 659 Summary: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer.
    • [No authors listed]
    • Obstet Gynecol. 2016 Mar;127(3):618-9. doi: 10.1097/AOG.0000000000001349.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: ACOG opinion Vaginal estrogen and women with ER pos breast ca

    • Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
    • Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, Senter L, Demsky R, Foulkes WD, Eng C, Karlan B, Tung N, Singer CF, Sun P, Lubinski J, Narod SA.
    • Breast Cancer Res Treat. 2016 Jan;155(2):365-73. doi: 10.1007/s10549-016-3685-3. Epub 2016 Jan 16.
    • Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.
    • Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF.
    • J Sex Med. 2015 Jan;12(1):189-97. doi: 10.1111/jsm.12713. Epub 2014 Oct 14.

    Related:

    Review:

    Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.

    • [Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer.]
    • Breda AS, Blaakær J.
    • Ugeskr Laeger. 2014 Sep 15;176(38). pii: V03130186.
    • [Article in Danish]
    • Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
    • Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB.
    • Menopause. 2014 Jul;21(7):763-8. doi: 10.1097/GME.0000000000000126.
    • Review
    • Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.
    • Chen Y, Bancroft E, Ashley S, Arden-Jones A, Thomas S, Shanley S, Saya S; Carrier Clinic Collaborators, Wakeling E, Eeles R.
    • Fam Cancer. 2014 Jun;13(2):197-203. doi: 10.1007/s10689-013-9697-9.
    • Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.
    • van Verschuer VM, Heemskerk-Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus-Linthorst MM, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C.
    • Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14.
    • The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study.
    • Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, Ghadirian P, Rosen B, Tung N, Kim-Sing C, Foulkes WD, Neuhausen SL, Senter L, Singer CF, Karlan B, Ping S, Narod SA; Hereditary Breast Cancer Study Group.
    • Gynecol Oncol. 2013 Jul;130(1):127-31. doi: 10.1016/j.ygyno.2013.03.027. Epub 2013 Apr 3.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: BRCA mutations and endometrial cancer

    Subject: Article request

    • Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
    • Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, Lester J, Karlan BY, Chen L.
    • Gynecol Oncol. 2013 May;129(2):364-71. doi: 10.1016/j.ygyno.2013.01.029. Epub 2013 Feb 4.
    • The management of menopausal symptoms in breast cancer survivors: case-based approach.
    • Lammerink EA, de Bock GH, Schröder CP, Mourits MJ.
    • Maturitas. 2012 Nov;73(3):265-8. doi: 10.1016/j.maturitas.2012.07.010. Epub 2012 Aug 9.
    • Review